

# Keyword Index for Volume 99

- 1q 1136  
<sup>131</sup>I 632  
 [<sup>18</sup>F]FDG 481  
 [<sup>18</sup>F]FLT 481,  
 2-deoxy-d-glucose 1842  
 2-methoxyoestradiol 1433  
 2-methoxyoestradiol-3,17-O,  
*bis*-sulphamate 1842  
 4T1 model 741  
 5-fluorouracil 716, 1020  
 7p 774  
 8q 774  
  
 α-fetoprotein 72  
 ABC transporter 1651  
 access to health care 1040  
 accrual rates 1967  
 ACSL3 314  
 ACSL3: *ETV1* fusion 314  
 active immunotherapy 350  
 adenovirus 1668  
 adherence 428, 1763  
 adiponectin 1246  
 adjuvant chemotherapy 597,  
 1226, 1232  
 adjuvant treatment 875  
 adolescent HPV vaccination  
 1908  
 adrenocortical carcinomas 1900  
 adult gliomas 1153  
 advanced breast cancer 1984  
 advanced cancer 1251  
 advanced gastric cancer 858  
 advanced solid tumours 1387  
 aetiology 545  
 AFP 72  
 age 1007, 1046  
 age at menarche 201  
 age inequalities in cancer care  
 1967  
 AIDS 800  
 AKT 1265, 1296  
 AKT1 488  
 albumin 1013  
 alcohol 805  
 allele-specific PCR 90  
 anaemia 14  
 anaplastic 781  
 androgen receptor 1743  
 angiogenesis 160, 321, 622,  
 1348, 1375, 1387, 1433, 1557,  
 1961, 2054  
 angiotensin receptors 160  
 antagonists and inhibitors 616  
 anthropometric factors 207  
 anthropometry 201  
 antiangiogenic 1197  
 anti-angiogenesis 734, 1204  
 antibody-drug conjugate 100  
 anti-cancer drug 1442, 2044  
 anti-CEA antibody targeting 632  
 anti-EGFR therapy 868  
 antiretroviral drugs 800  
 anxiety 1794  
 AP-1 1269, 2013  
 APC 1735  
 Apo-2L 294  
 apoptosis 283, 294, 841, 989,  
 1442, 1816, 1823  
 ARE1 -158 G/A polymorphism  
 (rs266882) 1743  
 aromatase inhibitor 428  
 AS1404 2006  
 ASA404 2006  
 asbestos 173, 822  
 asbestos removal 822  
 astrocytomas 160, 294  
 atypical squamous cells of  
 undetermined significance  
 (ASCUS) 563  
 automated fluorescence  
 microscope 789  
 awareness 1593  
 azathioprine 1276  
  
 β<sub>2</sub>-microglobulin 1453  
 basal cell carcinoma 1276  
 Bayesian analysis 1786  
 BCL-2 family proteins 1613  
 behavioural intention 225  
 bevacizumab 93, 1564  
 biliary tract cancer 811  
 biliary tract carcinoma 862  
 bioluminescent imaging 2037  
 biomarkers 655, 841, 1103  
 birth weight 1161, 1544, 1916  
*bis*-sulphamates 1433  
 biweekly schedule 455  
 BK virus 1383  
 bladder cancer 1383  
 BLT2 1064  
 BMI 1517, 1912  
*BNIP3* 727  
 body mass index 185, 527, 811,  
 1916  
 body size 196, 1517  
*BRAF* 83, 2020, 2065  
*BRAF* gene 1673  
 brain tumour 796  
 brain tumour stem cells 2044  
*BRCA1* 371, 974  
*BRCA1/2* 1302, 1534  
*BRCA2* 371, 974  
 breast 327, 1842  
 breast cancer 68, 196, 335, 387,  
 404, 408, 415, 423, 428, 513,  
 539, 597, 604, 704, 711, 774,  
 930, 974, 1000, 1089, 1170,  
 1185, 1221, 1226, 1357, 1369,  
 1433, 1502, 1534, 1544, 1623,  
 1644, 1763, 1775, 1940  
 breast cancer cell line 1246  
 breast cancer cells 481  
 breast cancer metastases 741  
 breast cancer risk 201, 207  
 breast cancer screening 1176  
 breast carcinoma 63, 611, 639  
 breast neoplasms 616  
 breast volume 1534  
  
 cachexia 2029  
 calcium 1539  
 cancer awareness 1221  
 cancer incidence 191  
 cancer registries 1923  
 cancer screening 655  
 cancer stem cells 387  
 cancer stromal cell 305  
 cancer survival 830, 1923  
 cancer susceptibility 670  
 cancer-associated fibroblasts  
 1375  
 capecitabine 584, 591, 858, 1316  
 carbonic anhydrase 9 1468  
 carboplatin 51, 894  
 carcinogenesis 1961, 2070  
 carcinoma 245, 1493  
 cardia 1506  
 case-control study 423  
 caspases 283  
 caveolin 1 327, 1684  
 caveolin 2 327  
 c-Cbl 1849  
 CCI-779 1197  
 CD133 100, 1285  
*CDKN2A* 364  
 cDNA microarray 335  
*C/EBPβ* 781  
 cell cycle 1635, 1823  
 cell invasion 1114  
 cell lines 1330  
 cell signalling 750  
 central obesity 527  
 Cervarix 1908  
 cervical cancer 225, 1096, 1216,  
 1557, 1651, 1929  
 cervical intraepithelial  
 neoplasia 239  
 cervical intraepithelial  
 neoplasia (CIN) 563  
 cetuximab 83, 455  
 c-Fos 1269  
 CFU<sub>gm</sub> 632  
 CGH 1136  
 ChA 72  
 chemoendocrine therapy 1564  
 chemokines 930, 1493  
 chemo-radiation 57  
 chemoradiotherapy 1020  
 chemosensitising 1832  
 chemosensitivity testing 760  
 chemotherapy 6, 23, 44, 51, 57,  
 63, 266, 283, 442, 481, 591,  
 695, 868, 900, 1000, 1395  
 chemotherapy response 387  
 chest X-ray 557  
 childhood 796, 1129, 1529, 1539,  
 1916  
 childhood cancer 179  
 childhood leukaemia 219, 1668  
 childhood nutrition 1517  
 China 196, 811  
 CHK2 or CHEK2 (checkpoint  
 kinase 2) 1302  
 choroid 1673  
 chromosome damage 670  
 chronic myelogenous leukaemia  
 387  
 CI-1040 2020  
 ciliary body 1673  
 circulating tumour cells 789,  
 841  
 cisplatin 167, 442, 852  
 c-KIT 2065  
 claudin-4 491  
 clear cell carcinoma 1197  
 clinical trials 1593, 1967  
 coffee 1534  
 cohort study 191, 1165, 1946  
 collagen IV 68  
 colon cancer 966, 2094  
 colorectal 275, 1285  
 colorectal cancer 133, 136, 266,  
 459, 532, 632, 716, 727, 1046,  
 1050, 1239, 1316, 1511, 1607,  
 1718, 1729, 1867, 1923, 1991,  
 2088  
 colorectal, prostate and ovarian  
 cancer 789  
 combination 1  
 combination therapy 689  
 combined modality therapy 900  
 combretastatin 321  
 common gene activation 1307  
 community 1763  
 compliance 428, 1593  
 concurrent chemoradiation 167  
 contralateral cancer 539  
 corticosteroids 23  
 cost-effectiveness 230, 557, 1984  
 Cox regression 179  
 CpG island 136  
 cribriform patterns in thyroid  
 tumour 1874  
 c-Src activation 1769  
 CT screening 557  
 curative surgery 1046  
 cure 219  
 CXCL13 930  
 CXCR4 1623, 1695  
 cyclooxygenase-2 1729  
 CYP1B1 1056  
 CYP2C19 1251  
 CYP3A4 1239  
 CYP1A2 1534  
 Cyr61 1656  
 cystine transporter 464  
 cytochrome P-450 2D6 616

- cytogenetic 1673  
 cytokeratins 841  
 cytotoxic agents 1
- dasatinib 1074  
 deep vein thrombosis 1034  
 definitive chemoradiotherapy 1586  
 depression 1794  
 depressive mood 1408  
 deprivation 1923  
 dermcidin 126  
 dexamethasone 2054  
 diabetes 1380  
 diagnostic marker 939  
 dietary folate 816  
 dietary patterns 191, 1511  
 differential expression 1136  
 differentiation 1849  
 disease progression 1572  
 disease-free survival 966  
 disease-specific survival 539, 1476  
 distant metastases 513  
 distress 1975  
 diuretics 1522  
 DKK3 663  
 DLEC1 375  
 Dll4 1204  
 DMXAA 2006  
 DNA methylation 136  
 DNA microarray 1484, 1635  
 DNA-repair genes 1050  
 docetaxel 852, 1426, 1832, 2054  
 dose 275, 722  
 dose fractionation 632  
 dose intensity 253, 1226  
 dose reduction 259  
 doxorubicin 442, 1816  
 drug metabolism 1251  
 drug resistance 118, 387, 464, 473, 1808  
 drug targeting 392, 900, 1256  
 Du145 1656  
 dynamic MRI 321
- early life 796, 1544  
 eastern Europe 1912  
 E-cadherin 1832  
 economic evaluation 1232  
 economics 1991  
 ECX 868  
 efficacy 584  
 efficiency 2001  
 EGCG 647, 1056  
 EGFR 83, 245, 341, 911, 923, 1056  
 EGFR inhibitors 473  
 EGFR-targeting drugs 1  
 EGFRvIII 341  
 elderly patients 51, 584, 1586  
 elective 1046  
 EndMT 1375  
 endocrine-responsive breast cancer 1564  
 endometrial adenocarcinoma 1034  
 endometrial cancer 434, 1651
- endometrial stromal sarcoma 1210  
 endosialin 1348  
 endothelial 1204  
 endothelial-to-mesenchymal transition 1375  
 Endothelin-converting enzyme-1 (ECE-1) 1114  
 endothelium 1256, 1375  
 engineered antibody 1415  
 enzastaurin 750  
 ependymoma 1129, 1136  
 EphA2 1074  
 EPIC Study 191  
 epidemiology 1522, 1529, 1946  
 epidermal growth factor receptor 90, 1729, 1757  
 epigenetics 136  
 epirubicin 858  
 epithelial 1476  
 epithelial cell adhesion molecule (EpcAM) 1635  
 epithelial-mesenchymal interactions 151  
 epoetin- $\beta$  14  
 Epstein-Barr virus 1816  
 ErbB 1415  
 ERCC1 167  
 ERG 847  
 ERK1/2 2020  
 erlotinib 93, 911  
 ER-positive breast cancer 1769  
 ethnicity 1040, 1757  
 ETS 847  
 Ets-1 1348  
 ETV1 314  
 EXE 858  
 exercise 30  
 expert rating scale 37  
 exploratory trial 415
- faecal tumour M2 pyruvate kinase 133  
 false-positive cases 239  
 familial predisposition 1748  
 familial risk 536  
 family history of breast cancer 1007  
 Fas ligand 502, 1600  
 Faslodex 1984  
 fatigue 23, 30, 1408  
 FBLN1 2083  
 female neoplasms 816  
 fibroblast growth factor receptor 2, 10, 305  
 fibrosis 1375  
 focus genes 1307  
 FOLFOX 1395  
 follow-up 704  
 Frizzled 143  
 FTIR microspectroscopy 1859  
 fuel 1934  
 fulvestrant 1984  
 fusion 847
- G3 endometrioid endometrial carcinoma 768  
 GA733 1290
- gallstones 811  
 gastric 100  
 gastric adenocarcinoma 949  
 gastric cancer 126, 584, 1307, 1322, 1802, 2083  
 gastrointestinal stromal tumour 448, 1600  
 gemcitabine 760, 862, 1387  
 GEMOX 862  
 gender 1506  
 gene expression 1330  
 gene expression profiling 1307, 1729, 1884  
 gene regulation 978, 1246  
 gene signature 1884  
 genetic susceptibility 536, 1748  
 genome profiling 387  
 genomic instability 1121  
 genotyping 563  
 germ cell tumour 1748  
 $\gamma$ H2AX 1129  
 Gleason grade 1859  
 glioblastoma 294, 1678, 2044  
 glioma 185, 294, 1144  
 glomerular filtration rate 894  
 glucose level 1380  
 glutathione 464  
 glycaemic index 434, 1170  
 glycaemic load 434, 1170  
 glycolysis 989  
 GOLPH2 939  
 GP73 939  
 granulocyte colony-stimulating factor 253  
 Great Britain 822  
 Greece 191  
 green tea 1179  
 green tea polyphenol 647  
 group rehabilitation 1975  
 GSTP1 1316  
 GTG banding (G-bands after trypsin and giemsa) 1302  
 Guthrie card 1668
- H19* 1891  
 hCG $\beta$  72  
 HDAC inhibitors 1623  
 head and neck cancer 57, 93, 167  
 health-related quality of life 1975  
 height 185, 1916  
 hepatitis C 805  
 hepatoblastoma 1891  
 hepatocarcinogenesis 151  
 hepatocellular 100  
 hepatocellular carcinoma 143, 805  
 hepatocyte growth factor 1623  
 HER family 1775  
 HER-2 68, 520  
 HER-2/neu 341  
 hereditary non-polyposis colorectal cancer 1726  
 heritable tumour syndromes 683  
 heterogeneity 1673  
 HIF-1 $\alpha$  459, 1442
- HIF-2 1348  
 high-risk HPV 404  
 highly sensitive *in situ* hybridisation 350  
 histone deacetylase 689  
 HIV 800  
 Hiwi 1083  
 HL60 670  
 HLA class I antigen 1462  
 HNF3 $\beta$ /FoxA2 781  
 HNSCC 357  
 home 1934  
 hormonal therapy 611  
 hormone receptor 196  
 hormone receptor positive 1984  
 hormone refractory 1296  
 hormones 1161  
 HPV 214, 230  
 HPV-16 408  
 HPV prevalence 1929  
 human chorionic gonadotrophin subunit  $\beta$  72  
 human papilloma virus (HPV) 225, 408, 563  
 human tissue kallikreins 1103  
 hypermethylation 357  
 hypertension 1912  
 hypothyroidism 448  
 hypoxia 727, 1348, 1442, 1468  
 hysterectomy 1216
- Id-1 1557, 1832  
 Id-1 gene 404  
 IGF binding protein 3 1096  
*IGF1R* 83  
*IGF2* 1891  
 IGFs 1357  
 imatinib 734, 1600  
 immune evasion 1867  
 immune function 2029  
 immunohistochemistry 321, 327, 335, 639, 939, 957, 1285, 1453, 1704, 1712  
 immunosuppression 1276  
 implementation 415  
*in utero* 545  
 incidence 176, 182, 1502, 1940  
 Indonesia 214  
 induction 57  
 infection 1529  
 inflammation 1251, 2029, 2070  
 inflammatory breast cancer 1735  
 inflammatory cells 1013  
 information 1908  
 informed 1007  
 infrared spectroscopy 1859  
 inhibitor 689, 911  
 inositol hexakisphosphate 1613  
 insulin-like growth factor-1 receptor 1096  
 integrative approach 1307  
 integrin  $\beta$ 1 1684  
 intercostobrachial neuropathy 604  
 intra-uterine growth 179  
 intraperitoneal therapy 2037  
 invasion 663, 1322, 1453

- involution 1369  
 ionising radiation 1940  
 IPMN 1064  
 ipsilateral breast relapse 539  
 IR (ionising radiation) 1302  
 irinotecan 275, 455, 577, 1239, 1316, 1607  
 irradiation 93  
 isothiocyanates 1823  
 Italy 173, 225  
  
 Jak-Stat pathway 2044  
 Japan 176, 1502, 1179  
  
 Kaposi sarcoma 800  
 Kdr 1204  
 Ki-67 1013, 1121  
 Ki-67/MIB-1 72  
 kidney cancer 1912  
 KIT 2065  
*KLHL9* 364  
*KLK6* 1484  
*KLK10* 1484  
 knowledge 1007  
*KRAS* 83, 245, 923, 2020  
 kRT-PCR 1775  
  
 lapatinib 711  
 laser microdissection 1735  
 laser-capture microdissection 1849  
 lentivirus 622  
 leukaemia 1529  
 leukotriene B<sub>4</sub> 1064  
 life expectancy 1991  
 liposomes 392, 1256  
 liquid-based cytology (LBC) 563  
*Listeria monocytogenes* 741  
 LIV-1 774  
 liver metastasis 350, 716, 957, 1729  
 LKB1 245, 683  
 localised 1027  
 locoregional recurrence 1121  
 long-term effects 30  
 longitudinal study 1794  
 loss of heterozygosity 1891  
 loss of imprinting 1891  
 low-dose rate exposure 1940  
 low-grade squamous intraepithelial lesion (LSIL) 563  
 LPA 1322  
 lung cancer 173, 557, 683, 852, 911, 1179, 1635, 1757, 1934  
 LXXLL motif 639  
 LY294002 2013  
 lymphangiogenesis 110  
 lymphoid leukaemia 488  
 lymphoma 1387  
  
 MAGE-A protein 350  
 MAGE-A10 mRNA 350  
 Mage-b DNA vaccine 741  
 MAL 1802  
 malignancy 545  
 malignant neoplasms 1549  
 malignant pleural mesothelioma 44, 51  
 mammary epithelial cell 1246  
 mammographic density 1369, 1539  
 mammography 1007, 1176  
 mammography screening 1185  
 MAPK 1089, 1823  
 margins 357  
 marker expression 491  
 mass screening 239  
 maternal age 1161  
 MDA-MB-231 1056  
*MDM2* 1144  
 Mdm2 SNP309 78  
 Mediterranean diet 191  
 MegaFasL 1600  
 melanoma 536, 1265, 1673, 1678, 2065  
 melanoma-prone families 364  
 meningioma 182, 185  
 menopausal status 196  
*MET* 83, 911  
 meta-analysis 434, 1170, 1340  
 metabolism 989  
 metastasis 110, 398, 923, 957, 1718  
 metastatic breast cancer 1572  
 metastatic colorectal cancer 455, 577, 722  
 metastatic gastric cancer 1402  
 metastatic melanoma 734  
 methionine 816  
 methylation 1735, 2083  
 methylation-specific PCR 1735  
 microarrays 398, 768, 1330, 1729, 1884  
 microenvironment 1484  
 microsatellite instability 1607, 1726, 1867  
 microtubule 1842  
 microvessel density 321, 1013, 1961  
 middle aged 239  
 midkine 655  
 MI-ER1 639  
 migration 1322, 1453, 1493  
 mismatch repair 375  
 mitochondria 989, 2088  
 mitomycin C 591  
*MnSOD* 283  
 modelling 1991  
 molecular diagnosis 1859  
 molecular markers 2001  
 mortality 173, 253, 822, 1549, 1763, 1934  
 motesanib diphosphate 1387  
 motility 520  
*MRE11* 1607  
 mRNA 1775  
 MSC 622  
 MT1-MMP 663  
 mTOR 1056  
 mTORC2 1197  
 MUC1 978  
 MUC4 520, 949  
 mucin 949  
 mucosal 2065  
 multiparametric analysis 1103  
 multiple primary neoplasm 1340  
 multiplex ELISA 841  
 multiplex ligation-dependent probe amplification 364  
 muscle strength 30  
 mutation screening 90  
 mutations 245, 488, 923, 1265, 2020  
*MYCN* gene 1027  
  
 nanomedicines 392, 900  
 National audit 695  
 national cancer statistics 830  
 natural killer-cell malignancies 1816  
 NB7M 1823  
 NEAT 1226  
 neoadjuvant 1020  
 neoplasm 1408, 1506  
 neprilysin 1114  
 NET1 1322  
 network mapping 1307  
 neuroblastoma 1027, 1165  
 neuroendocrine markers 1330  
 neuroendocrine tumours 72, 1330  
 neuropathic pain 604  
 neuropilin 1153  
 Nfkb1 2070  
 niacin 816  
 NLS (nuclear localisation signal) 1302  
 non-clear cell histology 259  
 non-Hodgkin's lymphoma 253  
 non-seminoma 1517  
 non-small cell lung cancer 245, 750, 852, 2006, 2013  
 normal mucosa 136  
 Norway 1165  
 Notch1 1204  
 Nrf2 2070  
 NSCLC 375, 923, 1476  
 nuclear 1769  
 nuclear factor- $\kappa$  B 1816  
 nuclear localisation 639  
 nucleoside transporter 760  
 nucleosomal DNA 841  
 nutrition 2029  
  
 obesity 527, 811, 995  
 occupational exposure 822  
 oesophageal cancer 126, 1020, 1395, 1586  
 oesophageal squamous cell carcinoma 1462, 1468  
 oesophagogastric cancer 868  
 oesophagus 1506  
 oestrogen receptor 639, 774  
 older women 1221  
 oral cancer 1121  
 oral cancer invasion 647  
 oral contraceptive 1534  
 oral squamous cell carcinoma 655, 1453  
 organ transplant recipients 1276  
 orthotopic 93, 110  
 outcome 727  
 ovarian cancer 283, 341, 434, 520, 1103, 1269, 1794, 1823, 1916, 2020, 2037  
 overdiagnosis 1176  
 oxaliplatin 577, 858, 862, 1020, 1050, 1395  
  
 p14<sup>ARF</sup> 364, 1144  
 p16<sup>INK4a</sup> 110, 364  
 P38 1808  
 p53 118, 974  
 p53 pathway 78  
 paclitaxel 1678, 2037  
 paediatric oncology patient 23  
 paediatrics 894  
 pancreas 622  
 pancreatic cancer 6, 110, 126, 305, 464, 527, 760, 1064, 1074, 1083, 1290, 1484  
 pancreatic cancer progression 1695  
 PanIN 1064  
 papillary 781  
 papillary thyroid carcinoma 1874  
 par6 1476  
 parents 1908  
 parity 1161  
 patient values 875  
 patient-doctor agreement 415  
 PCa 1656  
 PC-DFA 1859  
 pemetrexed 51, 750  
 perception 1593  
 perinatal 1165, 1544  
 PET 481  
 Peutz-Jeghers syndrome 683  
 pharmacodynamics 1579  
 pharmacogenetics 716, 1050, 1251  
 pharmacogenomic 1757  
 pharmacokinetics 1239, 1387, 1433, 1579  
 pharmacology and therapeutic use 616  
 pharmacovigilance 253  
 phase I 1579  
 phase II 734  
 phosphatase 1718  
 phosphatidylinositol 3-kinase pathway 2013  
 photosensitising reaction 1522  
 physical activity 1408  
 physical status 408  
 Physicians' Health Study 1743  
 PKC $\alpha$  1808  
 PKC $\delta$  1808  
 plasma D-dimer 1034  
 platelet-derived growth factor receptor 1426  
 pleural cancer 173  
 ploidy 513, 1121  
 PMPs 604  
 polymer therapeutics 900  
 polymers 392  
 polymorphisms 716, 978, 1050, 1357  
 population based 214, 1506  
 positivity criterion 415  
 positron emission tomography 989  
 postnatal growth 1544  
 postoperative pain 604  
 potassium channels 989

- PPAR $\gamma$  2044  
 PRAME 398  
 prediction of therapy 1103  
 predictions 1549  
 predictive value 1775  
 pre-malignant 1961  
 prenatal infection 1668  
 preoperative therapy 852, 1564  
 prevalence 214  
 prevention 532, 995  
 primary breast cancer 1013  
 primary chemotherapy 68  
 primary culture 1678  
 primary tumour 923  
 principal components analysis 1511  
 PRL-3 1718  
 PRMT1 2094  
 procoagulants 1000  
 prognosis 160, 335, 341, 357, 375, 398, 539, 655, 1083, 1089, 1129, 1285, 1462, 1468, 1651, 1712, 2094  
 prognostic factors 1027, 1210, 1269, 1402  
 prognostic indicator 1557  
 prognostic marker 1802, 1884  
 prognostic value 1775  
 progression 1269  
 proliferation 335, 1635, 1635, 1884  
 proliferation signature 966  
 proliferative activity 513  
 prominin-1 100  
 promoter hypermethylation 1802  
 promoter methylation 375  
 promoters 1144  
 prophylactic HPV vaccine 'Cervarix $\text{\textcircled{O}}$ ' 1929  
 prospective cohort studies 176, 1179, 1502, 1511  
 prospective study 448  
 prostaglandin E $_2$  502  
 prostate 1296, 1842  
 prostate cancer 78, 126, 176, 314, 371, 491, 847, 939, 1040, 1114, 1426, 1613, 1743, 1786, 1832, 1849, 1859, 2054  
 proteasome inhibitors 1613  
 protein arginine methyltransferase 2094  
 protein kinase C $\beta$  750  
 protein kinase C $\delta$  1644  
 protein tyrosine kinases 734  
 PSA gene 1743  
 pseudomyxoma peritonei 591  
 psycho-oncology 37  
 psychosocial distress 37  
 psychosocial support 1975  
 PTCH gene 1276  
 PTEN 341, 1089, 1296  
 PTK6 (BRK) 1089  
 pulmonary 597  
 pulmonary thromboembolism 1034  
  
 QMSP 357  
 Q-TWiST 111  
 quality of life 30, 415, 1226  
  
 quality-adjusted survival 711  
 Rac1 1656  
 RAD50 1607  
 radiation 545, 1216, 1946  
 radiation sensitivity 670  
 radioimmunotherapy 632  
 radiology 1185  
 radiosensitisation 1442  
 radiotherapy 63, 266, 900, 1395  
 radon 1946  
 randomised clinical trial 442  
 rapamycin 1197  
 receiver operating characteristic curve 1712  
 receptor tyrosine kinase 1074  
 RECK hypermethylation 647  
 record-linkage study 805  
 rectal cancer 1232, 1712, 1923  
 recurrence 357  
 registries 182  
 regulation 502  
 regulatory T cells 1867  
 rehabilitation 30  
 relative survival 1786  
 renal cell cancer 259, 448, 1380  
 renal function 894  
 resection 266  
 residual disease 1216  
 resistance 911  
 response 275, 1020  
 RET/PTC3 and E7 transgenic mice 1874  
 review 683  
 RFLP 78  
 RhoA 1322  
 riboflavin 816  
 risk 1369, 1522, 2088  
 risk factors 179, 545  
 risk modelling 557  
 RNA and protein 491  
 RNAi 1695  
  
 S-1 584  
 S100 proteins 1136  
 safety 584  
 SAGE 1136  
 salivary adenoid cystic carcinoma 90  
 salivary glands 90  
 Sam68 1089  
 sandwich ELISA 768  
 schedule dependency 1808  
 schools 1908  
 screening 133, 532, 557  
 second cancers 253, 536, 611  
 second-line chemotherapy 1402  
 securin 335  
 semaphorin 1153  
 seminoma 1517  
 serine proteases 1103  
 serotonin reuptake inhibitors 616  
 serum collagen IV 68  
 serum markers 768, 930  
 service screening 423  
 sex steroids 201  
 shared decision-making 875  
 signalling pathways 1623  
 signet ring cell carcinoma 949  
  
 Singapore Chinese 1511  
 single and multiple HR cases 1929  
 single nucleotide polymorphism 1340  
 size at birth 201  
 skin cancer 1522  
 sleep duration 176, 1502  
 sleeping problems 1408  
 Smad7 957  
 small-cell lung cancer 442  
 smoking 1161, 1912  
 smooth-muscle myosin 1726  
 Snail 1900  
 SNP309 1144  
 socioeconomic deprivation 830  
 soy 196  
 spatial models 1786  
 splicing 978  
 squalene epoxidase 774  
 squamous cell carcinoma 167  
 squamous cell carcinoma of the head and neck 1684  
 Src 1684  
 stage IB/II 852  
 stage-III 1718  
 STK11 683  
 stomach cancer 350, 1704  
 stool testing 133  
 stopping rule 2001  
 stove 1934  
 stromal 1476  
 SULT1A1 1340  
 sunitinib 259, 448, 1380  
 suppressor 1114  
 surgery 63  
 survival 14, 63, 219, 266, 398, 1013, 1046, 1210, 1269, 1285, 1316, 1357, 1426, 1572, 1900, 2001  
 survival analysis 1704  
 sustained chemotherapy 2037  
 Swiss HIV cohort study 800  
 systemic therapy 695  
  
 TAM67 2013  
 tamoxifen 428, 616, 1056, 1763, 1769  
 targeted therapy 473, 1290  
 TEAD1 1849  
 Techa River 1940  
 teenagers and young adults 830, 1967  
 tegafur-uracil 577  
 telatinib 1579  
 telephone follow-up 704  
 telomerase 1129  
 testicular cancer 1517, 1748  
 testicular microlithiasis 1748  
 TGF- $\beta$ 1 957, 1357  
 thiamin 816  
 thymidine kinase 481  
 thymidylate synthase 716  
 thyroid cancer 781  
 tissue array analysis 1704  
 tissue microdissection 1083  
 TMRSS2 847  
 tobacco related cancer 1340  
 tocotrienol 1832  
  
 topoisomerase II $\alpha$  670  
 toxicity 259, 275, 597, 1316  
 TP53 727, 1144  
 T $_{pot}$  1678  
 transcript 978  
 transcription 663  
 translocation 847  
 transplant recipients 1383  
 treatment guidelines 875  
 treatment preferences 875  
 trefoil factor 768  
 trends 219, 830, 1549  
 trichostatin A 1623  
 TROP2 1290  
 tumour advancement 1557  
 tumour antigen 398  
 tumour expression 930  
 tumour growth 1493  
 tumour hypoxia 459  
 tumour immune evasion 502  
 tumour immunity 1867  
 tumour marker 72, 1712  
 tumour microenvironment 118  
 tumour proliferation 2037  
 tumour stroma 118, 151  
 tumour suppressor gene 2083  
 tumour-infiltrating lymphocyte 1704  
 tumour-VDA 2006  
 tyrosine kinase inhibitor 1380, 1579  
  
 UFT 577, 722  
 UGT1A1\*28 275  
 UGT1A1 gene polymorphism 1239  
 ultrasound 1748  
 U-miners 1946  
 upper aerodigestive tract cancer 1340  
 uracil-tegafur 1232  
 urban-rural 207  
 urothelial cell carcinoma 663  
 uterine cancer 611  
  
 vaccination 230  
 vaginal smears 239  
 vascular disrupting agents 1256  
 vascular endothelial growth factor receptor 1579  
 vascular maturity 321  
 VDA 2006  
 VEGF 622, 1153, 1380  
 venous thromboembolism 1000  
 vimentin 1476  
 vinorelbine 44  
 viral aetiology 1668  
 viral load 408  
 vitamin D 1539  
  
 waist-to-hip ratio 527, 811  
 waiting times 695  
 weight gain 995  
 weight loss 995  
 WNT 143, 1695  
 women 185  
  
 xCT 464  
 xenografts 1074  
 X-irradiation 1442